Afuco™ Anti-Human CD3E ADCC Therapeutic Antibody (NI-0401), ADCC Enhanced
Anti-CD3E ADCC Enhanced Antibody (NI-0401) is an ADCC enhanced antibody produced by our Afuco™ platform. NI-0401 is a monoclonal antibody (mAb) intended to alter auto-aggressive T-cell responses by targeting the T-cell receptor complex. A Phase I and Phase IIa clinical trial in Crohn's disease, and a Phase I / II open-label study in renal allograft transplantation have been completed.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-118CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CD3E |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C |